Edson Erkulvrawatr, MD
Interventional Pain Medicine · Las Vegas, NVNPI 1306053848
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,507 of the $6,277 with a category attached, or 87.7%. 13 manufacturers reported payments, led by Medtronic at 24.4% of the total. Reporting peaked in 2019 at $2,414 and has fallen 75.9% since, to $581 in 2025.
Across 100 payments — averaging $62.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Biotronik NRO, Inc.$1K
- Vertiflex, Inc.$1K
- Abbott$967
- Boston Scientific$614
- Biodelivery Sciences International, Inc.$282
- plus $811 from 7 others
What the payments were for
- Travel & lodging$70211%
- Food & beverage$5,50788%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $1,530 |
| Biotronik NRO, Inc. | 34 | $1,037 |
| Vertiflex, Inc. | 7 | $1,035 |
| Abbott | 13 | $967 |
| Boston Scientific | 7 | $614 |
| Biodelivery Sciences International, Inc. | 4 | $282 |
| Nevro Corp. | 2 | $229 |
| Saluda Medical Americas, Inc. | 1 | $143 |
| Stimwave Technologies Incorporated | 1 | $139 |
| Nalu Medical, Inc. | 2 | $119 |
| Scilex Pharmaceuticals Inc. | 7 | $108 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion ISS$802
- GENERAL PAIN MANAGEMENT$576
- Proclaim IPG$533
- INTELLIS ADAPTIVESTIM$396
- MYSTIM$316
- Prospera$250
- BELBUCA$249
- Senza Spinal Cord Stimulation System$196
- PENTA$170
- INCEPTIV$163
- KYPHON Balloon Kyphoplasty$163
- Evoke SCS$143
- StimQ Receiver Stimulator Kit Channel A US w Receiver$139
- StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver$139
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$139
- Freedom 4A Receiver Kit Channel A US w Receiver$139
- Freedom 8A Receiver Kit Channel A US w Receiver$139
- KYPHON EXPRESS II KYPHOPAK TRAY$114
How this compares
$6,277 in reported general payments places this provider in the 70th percentile of 32 interventional pain medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 381 | $12,653 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 312 | $10,992 |
| Diclofenac Sodium | 61 | $8,873 |
| BelbucaBuprenorphine Hcl | 11 | $8,675 |
| OxycontinOxycodone Hcl | 20 | $8,532 |
| LinzessLinaclotide | 14 | $8,183 |
| Xtampza ErOxycodone Myristate | 19 | $6,929 |
| Lidocaine | 44 | $6,480 |
| Buprenorphine | 24 | $6,466 |
| Oxycodone Hcl | 340 | $5,367 |
| Morphine Sulfate ErMorphine Sulfate | 145 | $4,148 |
| Gabapentin | 304 | $3,645 |
| Pregabalin | 147 | $3,125 |
| Morphine Sulfate | 63 | $2,229 |
| Naloxone Hcl | 34 | $2,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $61 | $15,60430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 32 interventional pain medicine providers in Nevada.
Other interventional pain medicine in Las Vegas
- Adam AntflickLas Vegas$26K
- Stephen GephardtLas Vegas$14K
- Jeremy LipshutzLas Vegas$13K
- Denys GoloshchapovLas Vegas$11K
- Alafuro OrueneLas Vegas$6K
- Dolue EzeanolueLas Vegas$5K
- Katherine TravnicekLas Vegas$5K
- Godwin MadukaLas Vegas$4K
- Daniel BurkheadLas Vegas$4K
- Haroon AndarLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.